HK1215583A1 - 靶向於不同的多種抗原的通用嵌合抗原受體表達免疫細胞及其生產方法及其用於治療癌症、感染和自身免疫障礙的用途 - Google Patents
靶向於不同的多種抗原的通用嵌合抗原受體表達免疫細胞及其生產方法及其用於治療癌症、感染和自身免疫障礙的用途Info
- Publication number
- HK1215583A1 HK1215583A1 HK16103488.5A HK16103488A HK1215583A1 HK 1215583 A1 HK1215583 A1 HK 1215583A1 HK 16103488 A HK16103488 A HK 16103488A HK 1215583 A1 HK1215583 A1 HK 1215583A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- same
- infections
- targeting
- cancer
- manufacturing
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 210000002865 immune cell Anatomy 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14182945.7A EP2990416B1 (en) | 2014-08-29 | 2014-08-29 | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1215583A1 true HK1215583A1 (zh) | 2016-09-02 |
Family
ID=51429114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16103488.5A HK1215583A1 (zh) | 2014-08-29 | 2016-03-24 | 靶向於不同的多種抗原的通用嵌合抗原受體表達免疫細胞及其生產方法及其用於治療癌症、感染和自身免疫障礙的用途 |
Country Status (9)
Country | Link |
---|---|
US (3) | US10611814B2 (zh) |
EP (2) | EP2990416B1 (zh) |
JP (2) | JP7215825B2 (zh) |
CN (3) | CN106574272B (zh) |
AU (2) | AU2015308499B2 (zh) |
CA (1) | CA2953276C (zh) |
ES (1) | ES2688035T3 (zh) |
HK (1) | HK1215583A1 (zh) |
WO (1) | WO2016030414A1 (zh) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
EP3029137B1 (en) * | 2014-12-06 | 2019-01-02 | GEMoaB Monoclonals GmbH | Genetic modified pluri- or multipotent stem cells and uses thereof |
US11014989B2 (en) * | 2015-01-26 | 2021-05-25 | Cellectis | Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy |
JP7010487B2 (ja) | 2015-08-17 | 2022-03-03 | ソウル大学校産学協力団 | 抗コチニン抗体が連結したキメラ抗原受容体およびその使用 |
CN107446051B9 (zh) * | 2016-05-31 | 2019-02-22 | 上海恒润达生生物科技有限公司 | 靶向cd19的嵌合抗原受体及其用途 |
JP7096249B2 (ja) * | 2016-09-04 | 2022-07-05 | ターグイミューン セラピューティクス アーゲー | dsRNAを標的化するためのキメラタンパク質 |
EP3315511A1 (en) | 2016-10-29 | 2018-05-02 | Miltenyi Biotec GmbH | Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens |
CN108250301A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多靶点嵌合抗原受体 |
EP3567101A4 (en) * | 2017-01-05 | 2020-12-02 | Korea Research Institute of Bioscience and Biotechnology | NATURAL KILLER CELL EXPRESSING AN ANTI-COTININ CHEMERIC ANTIGEN RECEPTOR |
CA3052523A1 (en) * | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
CA3054078A1 (en) * | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding cd33, nkg2d and cd16 |
US20200191774A1 (en) | 2017-02-27 | 2020-06-18 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
KR20200006526A (ko) * | 2017-03-28 | 2020-01-20 | 리브젠 바이오파마 홀딩스 리미티드 | 종양 미세 환경에서 면역 반응을 향상시키기 위한 치료제 및 방법 |
MX2019012017A (es) | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. |
MX2019012189A (es) | 2017-04-14 | 2020-12-10 | Juno Therapeutics Inc | Metodos para valorar la glucosilacion de la superficie celular. |
EP3634474A1 (en) | 2017-06-09 | 2020-04-15 | GEMoaB Monoclonals GmbH | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders |
EP3638262A4 (en) * | 2017-06-16 | 2021-03-24 | Mayo Foundation for Medical Education and Research | MATERIALS AND METHODS FOR INCREASING IMMUNE REACTION |
EP3642237A2 (en) | 2017-06-20 | 2020-04-29 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
KR20200019946A (ko) * | 2017-06-22 | 2020-02-25 | 재단법인 생물기술개발중심 | 표적 세포-의존적 T 세포 관여 및 활성화 비대칭 헤테로다이머 Fc-ScFv 융합 항체 포맷 및 암 치료에서 그 사용 |
CN107326014B (zh) * | 2017-07-31 | 2019-09-24 | 时力生物科技(北京)有限公司 | 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用 |
CN109468279A (zh) * | 2017-09-08 | 2019-03-15 | 科济生物医药(上海)有限公司 | 靶向gpc3的免疫效应细胞及其应用 |
KR20200055037A (ko) | 2017-09-19 | 2020-05-20 | 메사추세츠 인스티튜트 오브 테크놀로지 | 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도 |
AU2018365080A1 (en) * | 2017-11-10 | 2020-05-07 | Jura Bio, Inc. | Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases |
CN108048404B (zh) * | 2017-12-08 | 2020-12-01 | 新乡医学院 | 一种抗肿瘤nk细胞及其制备方法和应用 |
CN107974433B (zh) * | 2017-12-08 | 2020-12-01 | 新乡医学院 | 一种增强型抗肿瘤nk细胞及其制备方法和应用 |
EP3735425A1 (en) * | 2018-01-04 | 2020-11-11 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor specific for bdca2 antigen |
WO2019136305A1 (en) * | 2018-01-04 | 2019-07-11 | Neumedicines Inc. | Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer |
BR112020013910A2 (pt) * | 2018-01-08 | 2020-12-01 | H. Lee Moffitt Cancer Center And Research Institute Inc. | composições e métodos para alvejamento de cânceres que expressam cd99 |
US11696943B2 (en) | 2018-01-23 | 2023-07-11 | Vanderbilt University | Self-antigen specific T-cells as vaccines for augmenting engraftment and stability of autologous transfer |
CN108017717B (zh) * | 2018-01-24 | 2019-08-16 | 首都医科大学宣武医院 | 一种用于体外高效定向扩增的嵌合抗原受体及其应用 |
PT110526B (pt) | 2018-01-26 | 2021-02-04 | Univ Nova De Lisboa | Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais |
US20200390814A1 (en) * | 2018-02-02 | 2020-12-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
WO2019157366A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
AU2019222560A1 (en) | 2018-02-17 | 2020-08-27 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
TW201942134A (zh) * | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
AU2019224051A1 (en) | 2018-02-26 | 2020-09-03 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
EP3759491A1 (en) * | 2018-03-01 | 2021-01-06 | H. Hoffnabb-La Roche Ag | Specificity assay for novel target antigen binding moieties |
EP3774918A4 (en) * | 2018-03-27 | 2022-04-06 | Systimmune, Inc. | METHODS OF MANUFACTURE AND USE OF GUIDANCE AND NAVIGATION CONTROL PROTEINS |
US11945878B2 (en) | 2018-04-18 | 2024-04-02 | Abclon Inc. | Switch molecule and switchable chimeric antigen receptor |
WO2019222642A1 (en) * | 2018-05-18 | 2019-11-21 | Senti Biosciences, Inc. | Engineered immune cells and methods of use |
EP3797164A4 (en) * | 2018-05-21 | 2022-03-02 | Biosceptre (Aust) Pty Ltd | CHEMERA ANTIGEN RECEPTORS WITH MODIFIED BINDING DOMAINS AND USES THEREOF |
EP3581200A1 (en) * | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
JP7477112B2 (ja) * | 2018-06-19 | 2024-05-01 | ナンジン レジェンド バイオテック カンパニー,リミテッド | 操作された細胞およびその使用 |
CN110623980A (zh) * | 2018-06-25 | 2019-12-31 | 深圳宾德生物技术有限公司 | 靶向cd38的嵌合抗原受体t细胞在自身免疫性疾病中的应用 |
US20210283180A1 (en) * | 2018-07-06 | 2021-09-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Car t cell therapy to target t cell specific cancers |
US20210292760A1 (en) | 2018-07-26 | 2021-09-23 | Aratinga.Bio Tnp | Aptamer-Based CAR T-Cell Switch |
KR20210057730A (ko) | 2018-08-09 | 2021-05-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작 세포 및 이의 조성물 생성 방법 |
EP3620464A1 (en) | 2018-09-10 | 2020-03-11 | Miltenyi Biotec GmbH | Car cell having crosslinked disulfide bridge on antigen recognizing moiety |
BR112021004261A2 (pt) | 2018-09-11 | 2021-05-25 | Juno Therapeutics Inc | métodos para análise por espectrometria de massas de composições de células geneticamente modificadas |
CA3113618A1 (en) | 2018-09-28 | 2020-04-02 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
CN110964112B (zh) * | 2018-09-30 | 2023-05-02 | 重庆精准生物技术有限公司 | 增强抗psca嵌合抗原受体活性的人源化抗体及其应用 |
EP3877417A4 (en) * | 2018-10-30 | 2022-08-03 | Peter MacCallum Cancer Institute | B-SPECIFIC POLYPEPTIDES FOR THE ENGAGEMENT OF CAR-EXPRESSING IMMUNE CELLS WITH ANTIGEN-PRESENTING CELLS AND THEIR USES |
SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
CN109452229B (zh) * | 2018-11-19 | 2021-10-22 | 百奥赛图(北京)医药科技股份有限公司 | 狗源化pd-1基因改造动物模型的制备方法及应用 |
EP3946382A1 (en) | 2019-04-04 | 2022-02-09 | UMC Utrecht Holding B.V. | Modified immune receptor constructs |
CN114007642A (zh) | 2019-04-30 | 2022-02-01 | 森迪生物科学公司 | 嵌合受体及其使用方法 |
BR112021021200A2 (pt) | 2019-05-01 | 2021-12-21 | Juno Therapeutics Inc | Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos |
CA3136737A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
EP3990491A1 (en) | 2019-06-26 | 2022-05-04 | Massachusetts Institute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
CN114630908A (zh) | 2019-07-26 | 2022-06-14 | 艾夏卡法国有限公司 | 基于适配体的多特异性治疗剂 |
CN114502587A (zh) * | 2019-07-30 | 2022-05-13 | 普瑞文森生物有限公司 | 通过非耗竭性b细胞抑制剂降低免疫原性的方法和组合物 |
AU2020329881A1 (en) * | 2019-08-09 | 2022-03-24 | A2 Biotherapeutics, Inc. | Cell-surface receptors responsive to loss of heterozygosity |
US20220333132A1 (en) | 2019-09-03 | 2022-10-20 | Sana Blotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
WO2021047804A1 (en) | 2019-09-11 | 2021-03-18 | Miltenyi Biotec B.V. & Co. KG | In vitro method for transduction of t cells in the presence of malignant cells |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
KR20220146480A (ko) | 2020-01-28 | 2022-11-01 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 형질도입 방법 |
EP4100027A1 (en) | 2020-02-04 | 2022-12-14 | Miltenyi Biotec B.V. & Co. KG | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens |
WO2021178975A1 (en) * | 2020-03-06 | 2021-09-10 | Albert Einstein College Of Medicine | A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity |
EP3878464A1 (en) | 2020-03-09 | 2021-09-15 | Miltenyi Biotec B.V. & Co. KG | Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells |
EP3881866A1 (en) | 2020-03-16 | 2021-09-22 | GEMoaB GmbH | A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated response in a mammal |
WO2021202604A1 (en) | 2020-03-31 | 2021-10-07 | Sana Biotechnology, Inc. | Targeted lipid particles and compositions and uses thereof |
US20210371490A1 (en) | 2020-05-28 | 2021-12-02 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains |
WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
CN116472049A (zh) | 2020-06-30 | 2023-07-21 | 特尼奥生物股份有限公司 | 与bcma结合的多特异性抗体 |
KR102297396B1 (ko) * | 2020-07-29 | 2021-09-06 | (주)티카로스 | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 |
WO2022036150A1 (en) | 2020-08-13 | 2022-02-17 | Sana Biotechnology, Inc. | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions |
EP4200325A1 (en) | 2020-08-19 | 2023-06-28 | Astellas Pharma Inc. | Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor |
EP4210733A1 (en) | 2020-09-04 | 2023-07-19 | Miltenyi Biotec B.V. & Co. KG | System for inducible expression of an adapter in immune cells |
TW202227478A (zh) * | 2020-09-15 | 2022-07-16 | 德商拜恩迪克公司 | 對細胞靶向遞送的藥劑及方法 |
EP4216972A1 (en) * | 2020-09-25 | 2023-08-02 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
EP4251174A1 (en) * | 2020-11-24 | 2023-10-04 | City of Hope | Compositions and uses of psca targeted chimeric antigen receptor modified cells |
TW202235617A (zh) | 2020-12-11 | 2022-09-16 | 美商英特利亞醫療公司 | 用於減少細胞中ii類mhc之組合物及方法 |
AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
CR20230320A (es) | 2020-12-23 | 2023-10-23 | Intellia Therapeutics Inc | Composiciones y métodos para reducir los hla-a en una célula |
IL303473A (en) | 2020-12-31 | 2023-08-01 | Sana Biotechnology Inc | Methods and compositions for modulating CAR-T activity |
WO2022144836A1 (en) | 2020-12-31 | 2022-07-07 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
TW202242121A (zh) | 2021-01-11 | 2022-11-01 | 美商薩那生物科技公司 | 靶向cd8之病毒載體之用途 |
AU2022244229A1 (en) | 2021-03-22 | 2023-09-14 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
AU2022241654A1 (en) | 2021-03-22 | 2023-09-28 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
BR112023024231A2 (pt) | 2021-05-19 | 2024-01-30 | Sana Biotechnology Inc | Células t primárias rhd negativas hipoimunogênicas |
BR112023024434A2 (pt) | 2021-05-27 | 2024-02-20 | Sana Biotechnology Inc | Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas |
IL308836A (en) | 2021-05-28 | 2024-01-01 | Sana Biotechnology Inc | Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses |
EP4351633A1 (en) * | 2021-06-08 | 2024-04-17 | Biontech Cell & Gene Therapies Gmbh | Agents and methods for activation and targeting of immune effector cells |
AU2022309875A1 (en) | 2021-07-14 | 2024-01-25 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
EP4384544A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
IL310691A (en) | 2021-08-11 | 2024-04-01 | Sana Biotechnology Inc | Genetically modified primary cells for allogeneic cell therapy |
AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
AU2022327174A1 (en) | 2021-08-11 | 2024-02-15 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
EP4176895A1 (en) | 2021-11-08 | 2023-05-10 | AvenCell Europe GmbH | Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor |
TW202342757A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科附著醣蛋白 |
TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2023225569A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Manufacturing viral particles |
TW202409271A (zh) | 2022-06-16 | 2024-03-01 | 美商英特利亞醫療公司 | 用於減少細胞中之mhc 1類之組成物及方法 |
WO2023247727A2 (en) | 2022-06-23 | 2023-12-28 | Ehninger Dr Armin | Engineered human t cells comprising a switchable chimeric antigen cell surface receptor and methods for generating them |
WO2023250489A1 (en) | 2022-06-23 | 2023-12-28 | Avencell Therapeutics Inc. | Targeting modules against cd123 for use in a method for stimulating a chimeric antigen receptor-mediated immune response in a mammal |
EP4296281A1 (en) | 2022-06-23 | 2023-12-27 | AvenCell Therapeutics Inc. | Targeting modules against cd123 and a tag for use in a method for stimulating a universal chimeric antigen receptor-mediated immune response in a mammal |
EP4295860A1 (en) | 2022-06-23 | 2023-12-27 | Armin Ehninger | Engineered human t cells comprising a switchable chimeric antigen cell surface receptor and methods for generating them |
EP4342907A1 (en) | 2022-09-21 | 2024-03-27 | AvenCell Europe GmbH | Switchable chimeric antigen receptors and their use |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024078995A1 (en) | 2022-10-15 | 2024-04-18 | Miltenyi Biotec B.V. & Co. KG | Transduction of gammadelta t cells with pseudotyped retroviral vectors |
WO2024097314A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Methods and systems for determining donor cell features and formulating cell therapy products based on cell features |
WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
EP4382119A1 (en) | 2022-12-09 | 2024-06-12 | AvenCell Europe GmbH | A kit for use in the treatment of hematological cancer |
WO2024121297A1 (en) | 2022-12-09 | 2024-06-13 | Avencell Europe Gmbh | A kit for use in the treatment of hematological cancer |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4751181A (en) | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
CA1313818C (en) | 1987-06-03 | 1993-02-23 | Ross Leon Coppel | Nuclear antigen la |
US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
US7049136B2 (en) | 1991-03-07 | 2006-05-23 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
WO1997024373A1 (en) | 1995-12-29 | 1997-07-10 | Medvet Science Pty. Limited | Monoclonal antibody antagonists to haemopoietic growth factors |
EP1194167B1 (en) | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
ATE510855T1 (de) | 2000-03-06 | 2011-06-15 | Univ Kentucky Res Found | Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen |
CA2425862C (en) | 2000-11-07 | 2013-01-22 | City Of Hope | Cd19-specific redirected immune cells |
US7151164B2 (en) | 2002-02-14 | 2006-12-19 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
WO2006114115A1 (de) | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
WO2007043103A1 (ja) | 2005-09-30 | 2007-04-19 | Kansai Technology Licensing Organization Co., Ltd. | シェーグレン症候群診断法及び診断キット |
CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
PT2426148E (pt) * | 2009-04-27 | 2015-10-26 | Kyowa Hakko Kirin Co Ltd | Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue |
US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
DK2582390T3 (en) | 2010-06-15 | 2015-02-23 | Csl Ltd | Immune therapeutic approach involving cd123 (il-3r) antibodies and immune stimulating complex |
DE102010039015A1 (de) | 2010-08-06 | 2012-02-09 | Technische Universität Dresden | Linkerpeptid und seine Verwendung in Fusionsproteinen |
DE102010039018B4 (de) * | 2010-08-06 | 2013-02-28 | Technische Universität Dresden | Anti-La Antikörper und ihre Anwendung zum Immunotargeting |
EP2418491A1 (en) | 2010-08-10 | 2012-02-15 | Bioftalmik, S.L. | Method for the diagnosis of dry eye and blepharitis |
BR122021026169B1 (pt) * | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
CA3102782A1 (en) | 2010-12-14 | 2012-06-21 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
DE102011118022B4 (de) | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
EA201491572A1 (ru) * | 2012-02-22 | 2014-12-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиции и способы получения устойчивой популяции t-клеток, используемых для лечения злокачественного новообразования |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
HUE059815T2 (hu) | 2012-05-18 | 2022-12-28 | Aptevo Res & Development Llc | Bispecifikus SCFV immunofuziós (BIF) kötõdés a CD123-hoz és a CD3-hoz |
BR112015000657B1 (pt) | 2012-07-13 | 2023-12-05 | The Trustees Of The University Of Pennsylvania | Uso de uma célula geneticamente modificada para expressar um car |
ES2743738T3 (es) * | 2012-10-02 | 2020-02-20 | Memorial Sloan Kettering Cancer Center | Composiciones y métodos para inmunoterapia |
EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
CA2901115A1 (en) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of California | Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof |
WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
CA2926698C (en) | 2013-10-15 | 2021-06-22 | The California Institute For Biomedical Research | Chimeric antigen receptor t cell switches and uses thereof |
ES2845924T3 (es) | 2013-10-15 | 2021-07-28 | Scripps Research Inst | Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos |
US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
WO2015143224A1 (en) | 2014-03-19 | 2015-09-24 | Ambrx, Inc. | Chimeric antigen receptor-modified t-cells |
MX370272B (es) | 2014-03-19 | 2019-12-09 | Cellectis | Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. |
CN105194661B (zh) | 2014-06-26 | 2019-05-03 | 科济生物医药(上海)有限公司 | 时空可调性抑制病理性靶细胞的系统 |
PL3183268T3 (pl) | 2014-08-19 | 2020-09-07 | Novartis Ag | Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego |
EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
WO2016168769A1 (en) | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Chimeric receptor t cell switches for her2 |
JP2018538277A (ja) | 2015-11-23 | 2018-12-27 | トラスティーズ オブ ボストン ユニバーシティ | キメラ抗原受容体に関する方法および組成物 |
-
2014
- 2014-08-29 EP EP14182945.7A patent/EP2990416B1/en active Active
- 2014-08-29 ES ES14182945.7T patent/ES2688035T3/es active Active
-
2015
- 2015-08-26 EP EP15756392.5A patent/EP3186275A1/en active Pending
- 2015-08-26 CN CN201580043322.7A patent/CN106574272B/zh active Active
- 2015-08-26 JP JP2017530422A patent/JP7215825B2/ja active Active
- 2015-08-26 CA CA2953276A patent/CA2953276C/en active Active
- 2015-08-26 CN CN202210415817.XA patent/CN114774444A/zh active Pending
- 2015-08-26 AU AU2015308499A patent/AU2015308499B2/en active Active
- 2015-08-26 WO PCT/EP2015/069527 patent/WO2016030414A1/en active Application Filing
- 2015-08-26 US US15/504,012 patent/US10611814B2/en active Active
- 2015-08-26 CN CN202110933891.6A patent/CN114085855A/zh active Pending
-
2016
- 2016-03-24 HK HK16103488.5A patent/HK1215583A1/zh unknown
-
2019
- 2019-07-16 US US16/513,672 patent/US10766943B2/en active Active
-
2020
- 2020-01-31 AU AU2020200751A patent/AU2020200751B2/en active Active
- 2020-02-21 US US16/798,255 patent/US20210206828A9/en active Pending
-
2021
- 2021-01-28 JP JP2021012313A patent/JP2021072831A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2688035T3 (es) | 2018-10-30 |
CA2953276C (en) | 2023-08-29 |
AU2015308499A1 (en) | 2017-01-12 |
JP7215825B2 (ja) | 2023-01-31 |
US20170240612A1 (en) | 2017-08-24 |
EP2990416B1 (en) | 2018-06-20 |
AU2020200751B2 (en) | 2021-07-29 |
CN106574272A (zh) | 2017-04-19 |
CN114085855A (zh) | 2022-02-25 |
EP2990416A1 (en) | 2016-03-02 |
EP3186275A1 (en) | 2017-07-05 |
JP2017530724A (ja) | 2017-10-19 |
CN106574272B (zh) | 2022-04-29 |
AU2015308499B2 (en) | 2020-01-02 |
AU2020200751A1 (en) | 2020-02-20 |
JP2021072831A (ja) | 2021-05-13 |
CA2953276A1 (en) | 2016-03-03 |
US20200181228A1 (en) | 2020-06-11 |
US10611814B2 (en) | 2020-04-07 |
WO2016030414A1 (en) | 2016-03-03 |
CN114774444A (zh) | 2022-07-22 |
US20190352370A1 (en) | 2019-11-21 |
US10766943B2 (en) | 2020-09-08 |
US20210206828A9 (en) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1215583A1 (zh) | 靶向於不同的多種抗原的通用嵌合抗原受體表達免疫細胞及其生產方法及其用於治療癌症、感染和自身免疫障礙的用途 | |
IL279146A (en) | Reversible Universal Chimeric Antigen Receptor (RevCAR) Expressing Immune Cells Targeted to Multiple Different Antigens, Method for Their Production and Use for the Treatment of Cancer, Infections, and Autoimmune Disorders | |
IL280215A (en) | Cancer treatment using chimeric antigen receptor (CAR) against CD19 | |
IL290459A (en) | Modified t cells - targeted chimeric antigen receptor cs1 | |
IL280576B (en) | Chimeric antigen receptor T cells target il13ra2 | |
HK1251948A1 (zh) | 抗間皮素全人抗體以及靶向間皮素的免疫效應細胞 | |
EP3564266A4 (en) | NEW CHIMERA RECEIVER OF ANTIGEN AND CORRESPONDING USE | |
IL269538A (en) | Universal anti–CD22 chimeric antigen receptor engineered immune cells | |
EP3256492A4 (en) | Bi-specific chimeric antigen receptor and uses thereof | |
EP3274366B8 (en) | Chimeric antigen receptor | |
WO2016100985A3 (en) | Chimeric antigen receptors and methods of use thereof | |
EP3119425A4 (en) | Regulatable chimeric antigen receptor | |
EP3313892A4 (en) | Immune checkpoint chimeric antigen receptors therapy | |
HK1243099A1 (zh) | 抗bace1的抗體和其用於神經疾病免疫療法的用途 | |
IL268704B (en) | Formulations of antibodies against human rankl, and methods of using them | |
SG11201800872QA (en) | Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed | |
EP3177320A4 (en) | Human monoclonal antibodies against epha4 and their use | |
EP3211080A4 (en) | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | |
EP3381946A4 (en) | CHIMERIC ANTI-GENIC ANTI-SULFATE RECEPTOR OF PLACENTARY CHONDROITIN AND APPLICATION THEREOF | |
EP3204423A4 (en) | Human anti-vegfr-2/kdr antibodies | |
AU2015903719A0 (en) | Chimeric antigen receptor and uses thereof | |
AU2014902457A0 (en) | Chimeric antigen receptor and uses thereof |